CCR4 and peripheral T-cell lymphoma, not otherwise specified: Based on these results, mogamulizumab was approved in Japan in 2014 for relapsed/refractory CCR4-positive peripheral T-cell lymphoma and cutaneous T-cell lymphoma (26).